DK2441767T3

DK2441767T3 - Salinosporamider and methods of use thereof

Info

Publication number: DK2441767T3
Application number: DK11163737.7T
Authority: DK
Inventors: William H Fenical; Paul R Jensen; Tracy J Mincer; Robert H R Feling
Original assignee: Univ California
Priority date: 2003-06-20
Filing date: 2004-06-18
Publication date: 2015-08-24
Also published as: ES2546415T3; KR20120081637A; MX361003B; IL240236A0; PT2441767E; IL240236B; CY1116724T1; KR101315595B1; SI2441767T1

Description

DESCRIPTION

[0001] The invention relates to a pharmaceutical composition comprising an effective amount of a pharmaceutically acceptable carrier, an effective amount of a compound of formula (V) and sucrose

BACKGROUND INFORMATION

[0002] Neoplastic diseases, characterized by the proliferation of cells not subject to the normal control of cell growth, are a major cause of death in humans. Clinical experience in chemotherapy has demonstrated that new and more effective cytotoxic drugs are desirable to treat these diseases. Indeed, the use of anti-neoplastic agents has increased due to the identification of new neoplasms and cancer cell types with metastases to different areas, and due to the effectiveness of antineoplastic treatment protocols as a primary and adjunctive medical treatment for cancer.

[0003] Since anti-neoplastic agents are cytotoxic (poisonous to cells) they not only interfere with the growth of tumor cells, but those of normal cells. Anti-neoplastic agents have more of an effect on tumor cells than normal cells because of their rapid growth. Thus, normal tissue cells that are affected by anti-neoplastic agents are rapidly dividing cells, such as bone marrow (seen in low blood counts), hair follicles (seen by way of hair loss) and the Gl mucosal epithelium (accounting for nausea, vomiting, loss of appetite, diarrhea). In general, anti-neoplastic agents have the lowest therapeutic indices of any class of drugs used in humans and hence produce significant and potentially life-threatening toxicities. Certain commonly-used anti-neoplastic agents have unique and acute toxicities for specific tissues. For example, the vinca alkaloids possess significant toxicity for nervous tissues, while adriamycin has specific toxicity for heart tissue and bleomycin has for lung tissue.

[0004] Robert H. Feling et al, Angew. Chem. Int. Ed. 2003, 42(3), page 355-357 discloses Salinosporamide A, and indicates that this compound displays potent in vitro cytotoxicity against human colon carcinoma cells, non-small cell lung cancer cells, CNS cancer cells, melanoma cells and breast cancer cells.

[0005] William Fenical et al, Pharmaceutical News, 2002, 9, pages 480-494 discloses Salinosporamide A, and states that Salinosporamide A is an authenticated inhibitor of the intracellular proteasome, and is targeted towards the treatment of cancer.

[0006] WO 2005/002572 is citable against the claimed invention under Article 54(3) EPC. WO 2005/002572 discloses compounds of Formula I:

and indicates that these compounds may be used as anti-microbial, anti-cancer or antiinflammatory agents.

[0007] WO 2004/071382 is citable against the claimed invention under Article 54(3) EPC and describes compounds of Formula I:

[0008] WO 2004/071382 indicates that these compounds may be useful for treatment of cancer.

[0009] Thus, there is a continuing need for anti-neoplastic agents that are effective in inhibiting the proliferation of hyperproliferative cells while also exhibiting IC50 values lower than those values found for current anti-neoplastic agents, thereby resulting in marked decrease in potentially serious side effects.

SUMMARY OF THE INVENTION

[0010] The present disclosure is based on the discovery that certain fermentation products of the marine actinomycete strains CNB392 and CNB476 are effective inhibitors of hyperproliferative mammalian cells. The CNB392 and CNB476 strains lie within the family Micromonosporaceae, and the generic epithet Salinospora has been proposed for this obligate marine group. The reaction products produced by this strain are classified as salinosporamides, and are particularly advantageous in treating neoplastic disorders due to their low molecular weight, low IC50 values, high pharmaceutical potency, and selectivity for cancer cells over fungi.

[0011] In one embodiment of the invention, there is provided a pharmaceutical composition comprising an effective amount of a pharmaceutically acceptable carrier and an effective amount of a compound having the structure (V):

V wherein the pharmaceutical composition further comprises sucrose.

[0012] In a further embodiment of the invention, there are provided compounds having the structure (II):

R-l to R3 are each independently -H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen, amino, amido, carboxyl, -C(0)H, acyl, oxyacyl, carbamate, sulfonyl, sulfonamide, or sulfuryl;

Each R4 is independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl; E-| to E4 are each independently -0, -NR5, or -S, wherein R5 is -H or C-|-C6 alkyl; and x is 0 to 8.

[0013] In another embodiment of the invention, there are provided compounds having the structure (III):

R-l to R3 are each independently -H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen, amino, amido, carboxyl, -C(0)H, acyl, oxyacyl, carbamate, sulfonyl, sulfonamide, or sulfuryl, each R4 is independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, E-| to E4 are each independently -0, -NR5, or -S, wherein R5 is -H or C-|-C6 alkyl, and x is 0 to 8. mm ai in ctiii

a fi irthor omhnriimont of the invention, there are provided compounds having the structure (IV): [0015] In a further embodiment of the invention, there are provided compounds having the structure (V):

[0016] The present disclosure describes articles of manufacture including packaging material and a pharmaceutical composition of the invention contained within the packaging material, wherein the packaging material includes a label which indicates that the pharmaceutical composition can be used for treatment of a mammalian cell proliferative disorder selected from pancreatic adenocarcinoma, central nervous system neoplasm, sarcoma of soft tissue, sarcoma of bone, head neoplasm, neck neoplasm, gastric neoplasm, thyroid neoplasm, stomach neoplasm, myeloma, bladder neoplasm, neuroendocrine neoplasm, non-Hodgkin's disease neoplasm and Hodgkin's disease neoplasm.

[0017] The pharmaceutical compositions of the invention can be used in methods for treating a mammalian cell proliferative disorder. Such a method can be performed for example, by administering to a subject in need thereof a pharmaceutical composition of the invention.

[0018] The present disclosure provides methods for producing a compound of structure V. Such a method can be performed, for example, by cultivating a culture of a Salinospora sp. strains CNB392 (ATCC #_) or CNB476 (ATCC PTA-5275) and isolating from the culture a compound of structure V.

BRIEF DESCRIPTION OF THE DRAWINGS

[0019]

Figure 1 depicts the chemical structure of an exemplary compound of the invention, Salinosporamide A, with relative stereochemistry.

Figure 2 depicts a phylogenetic tree illustrating the phylogeny of "Salinospora".

Figure 3 depicts the chemical structure of Etoposide, an anti-neoplastic agent in therapy against several human cancers.

Figure 4 compares the cytotoxic activity and dose response curves of Salinosporamide A and Etoposide.

Figure 5 is a block diagram depicting an exemplary separation scheme used to isolate Salinosporamide A.

Figures 6-14 set forth NMR, IR, and UV spectroscopic data used to elucidate the structure of Salinosporamide A.

Figure 15 sets forth the signature nucleotides that strains CNB392 and CNB476 possess within their 16S rDNA, which separate these strains phylogenetically from all other family members of the family Micromonosporaceae.

Figure 16 depicts the chemical structure of an exemplary compound of the invention, salinosporamide A (structure V), with absolute stereochemistry.

Figure 17 ORTEP plot of the final X-ray structure of salinosporamide A, depicting the absolute stereochemistry.

DETAILED DESCRIPTION OF THE INVENTION

[0020] The present invention provides a pharmaceutical composition comprising an effective amount of a pharmaceutically acceptable carrier and an effective amount of a compound having the structure of compound (V):

wherein the pharmaceutical composition further comprises sucrose.

[0021] The pharmaceutical composition is preferably in the form of a sterile injectable solution or a solid.

[0022] Preferably, the sterile injectable solution is an aqueous sterile injectable solution.

[0023] The pharmaceutical composition of the invention preferably further comprises an additional agent.

[0024] The invention also provides a pharmaceutical composition as defined herein for use in treating a mammalian cell proliferative disorder, wherein the disorder is selected from the group consisting of pancreatic adenocarcinoma, central nervous system neoplasm, sarcoma of soft tissue, sarcoma of bone, head neoplasm, neck neoplasm, gastric neoplasm, thyroid neoplasm, stomach neoplasm, myeloma, bladder neoplasm, neuroendocrine neoplasm, non-Hodgkin's disease neoplasm and Hodgkin's disease neoplasm.

[0025] Preferably the mammalian cell is human.

[0026] In a further embodiment of the invention, there are provided compounds having the structure (II):

wherein: R-l to R3 are each independently -H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen, amino, amido, carboxyl, -C(0)H, acyl, oxyacyl, carbamate, sulfonyl, sulfonamide, or sulfuryl;

[0027] In one embodiment, there are provided compounds having the structure (III):

wherein: R-l to R3 are each independently -H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen, amino, amido, carboxyl, -C(0)H, acyl, oxyacyl, carbamate, sulfonyl, sulfonamide, or sulfuryl, each R4 is independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, E-| to E4 are each independently -O, -NR5, or -S, wherein R5 is -H or C-|-C6 alkyl, and x is 0 to 8.

[0028] In still a further embodiment of the invention, there are provided compounds having the structure (IV):

[0029] In a further embodiment of the invention, there are provided compounds having the structure (V):

[0030] As used herein, the term "alkyl" refers to a monovalent straight or branched chain hydrocarbon group having from one to about 12 carbon atoms, including methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-hexyl, and the like.

[0031] As used herein, "substituted alkyl" refers to alkyl groups further bearing one or more substituents selected from hydroxy, alkoxy, mercapto, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aryloxy, substituted aryloxy, halogen, cyano, nitro, amino, amido, -C(0)H, acyl, oxyacyl, carboxyl, sulfonyl, sulfonamide, sulfuryl, and the like.

[0032] As used herein, "lower alkyl" refers to alkyl groups having from 1 to about 6 carbon atoms.

[0033] As used herein, "alkenyl" refers to straight or branched chain hydrocarbyl groups having one or more carbon-carbon double bonds, and having in the range of about 2 up to 12 carbon atoms, and "substituted alkenyl" refers to alkenyl groups further bearing one or more substituents as set forth above.

[0034] As used herein, "alkynyl" refers to straight or branched chain hydrocarbyl groups having at least one carbon-carbon triple bond, and having in the range of about 2 up to 12 carbon atoms, and "substituted alkynyl" refers to alkynyl groups further bearing one or more substituents as set forth above.

[0035] As used herein, "aryl" refers to aromatic groups having in the range of 6 up to 14 carbon atoms and "substituted aryl" refers to aryl groups further bearing one or more substituents as set forth above.

[0036] As used herein, "heteroaryl" refers to aromatic rings containing one or more heteroatoms (e.g., N, O, S, or the like) as part of the ring structure, and having in the range of 3 up to 14 carbon atoms and "substituted heteroaryl" refers to heteroaryl groups further bearing one or more substituents as set forth above.

[0037] As used herein, "alkoxy" refers to the moiety -Ο-alkyl-, wherein alkyl is as defined above, and "substituted alkoxy" refers to alkoxyl groups further bearing one or more substituents as set forth above.

[0038] As used herein, "thioalkyl" refers to the moiety -S-alkyl-, wherein alkyl is as defined above, and "substituted thioalkyl" refers to thioalkyl groups further bearing one or more substituents as set forth above.

[0039] As used herein, "cycloalkyl" refers to ring-containing alkyl groups containing in the range of about 3 up to 8 carbon atoms, and "substituted cycloalkyl" refers to cycloalkyl groups further bearing one or more substituents as set forth above.

[0040] As used herein, "heterocyclic", refers to cyclic (i.e., ring-containing) groups containing one or more heteroatoms (e.g., N, O, S, or the like) as part of the ring structure, and having in the range of 3 up to 14 carbon atoms and "substituted heterocyclic" refers to heterocyclic groups further bearing one or more substituents as set forth above.

[0041] The compound of the invention may be formulated into the pharmaceutical compositions as a natural or salt form. Pharmaceutically acceptable non-toxic salts include the base addition salts (formed with free carboxyl or other anionic groups) which may be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino-ethanol, histidine, procaine, and the like. Such salts may also be formed as acid addition salts with any free cationic groups and will generally be formed with inorganic acids such as, for example, hydrochloric, sulfuric, or phosphoric acids, or organic acids such as acetic, p-toluenesulfonic, methanesulfonic acid, oxalic, tartaric, mandelic, and the like. Salts of the invention include amine salts formed by the protonation of an amino group with inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like. Salts of the invention also include amine salts formed by the protonation of an amino group with suitable organic acids, such as p-toluenesulfonic acid, acetic acid, and the like. Additional excipients which are contemplated for use in the practice of the present invention are those available to those of ordinary skill in the art, for example, those found in the United States Pharmacopeia Vol. XXII and National Formulary Vol. XVII, U.S. Pharmacopeia Convention, Inc., Rockville, MD (1989).

[0042] The compound according to this invention contains an undefined asymmetric carbon atom. Thus the compound of the invention may occur as a racemate or racemic mixture, single enantiomer, diastereomeric mixture or individual diastereomer. The term "stereoisomer" refers to chemical compounds which differ from each other only in the way that the different groups in the molecules are oriented in space. Stereoisomers have the same molecular weight, chemical composition, and constitution as another, but with the atoms grouped differently. That is, certain identical chemical moieties are at different orientations in space and, therefore, when pure, have the ability to rotate the plane of polarized light. However, some pure stereoisomers may have an optical rotation that is so slight that it is undetectable with present instrumentation.

[0043] The undefined stereogenic carbon may be of R or S configuration. The terms "optically pure compound" or "optically pure isomer" refers to a single stereoisomer of a chiral compound regardless of the configuration of the compound.

[0044] The compound of the invention is shown below:

[0045] Salinosporamide A exhibits a molecular structure having a variety of functional groups (lactone, alkylhalide, amide, hydroxide) that can be chemically modified to produce synthetic derivatives. Accordingly, the compound of the invention, Salinosporamide A, provides an excellent lead structure for the development of synthetic and semisynthetic derivatives. Indeed, Salinosporamide A can be derivatized to improve pharmacokinetic and pharmacodynamic properties, which facilitate administration and increase utility of the derivatives as anti-neoplastic agents.

[0046] Salinosporamide A shows strong cytotoxic activity against human colon cancer cells in the HTC-116 cell assays. The IC 50 of 11 ng/mL exceeds the activity of etoposide (see Figure 3, IC50 828 ng/mL), an anticancer drug used for treatment of a number of cancers, by almost two orders of magnitude (see Figure 4). This high activity makes Salinosporamide A an excellent candidate for use in the treatment of various human cancers, especially slow growing, refractile cancers for which there are no therapies. Salinosporamide A is specific to inhibition of mammalian cells and shows little anifungal activity against Candida albicans (IC50 250 pg/mL) and no antibacterial activity (Staphylococcus aureus, Enterococcus faecium). The IC50 of Salinosporamide A is far lower than the strongest chemotherapeutic agents currently in use or in clinical trials.

[0047] Salinosporamide A is a fermentation product of the marine actinomycete strains CNB392 and CNB476. These strains are members of the order Actinomycetales, which are high G + C gram positive bacteria. The novelty of CNB392 and CNB476 is at the genus level. The CNB392 and CNB476 strains of "Salinospora" sp. were deposited on June 20, 2003, pursuant to the Budapest Treaty on the International Deposit of Microorganisms for the Purposes of Patent Procedure with the Patent Culture Depository of the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Md. 20852 U.S.A. under ATCC Accession Nos._and PTA-5275. respectively.

[0048] As is the case with other organisms, the characteristics of "Salinospora" sp. are subject to variation. For example, recombinants, variants, or mutants of the specified strain may be obtained by treatment with various known physical and chemical mutagens, such as ultraviolet ray, X-rays, gamma rays, and N-methyl-N'-nitro-N-nitrosoguanidine.

[0049] The compound of the invention can be prepared, for example, by bacterial fermentation, which generates the compound in sufficient amounts for pharmaceutical drug development and for clinical trials. The compound may be produced by fermentation of the actinomycete strains CNB392 and CNB476 in AIBfe+C or CKA-liquid media. Essential trace elements which are necessary for the growth and development of the culture should also be included in the culture medium. Such trace elements commonly occur as impurities in other constituents of the medium in amounts sufficient to meet the growth requirements of the organisms. It may be desirable to add small amounts (i.e. 0.2 mL/L) of an antifoam agent such as polypropylene glycol (M.W. about 2000) to large scale cultivation media if foaming becomes a problem. The organic metabolites can be isolated by adsorption onto an amberlite XAD-16 resin. For example, Salinosporamide A is isolated by elution of the XAD-16 resin with methanofdichlormethane 1:1, which affords about 105 mg crude extract per liter of culture. Salinosporamide A is then isolated from the crude extract by reversed-phase flash chromatography followed by reverse-phase FIPLC and normal phase FIPLC, which yields 6.7 mg of Salinosporamide A. Figure 5 sets forth a block diagram outlining isolation and separation protocols for invention compounds.

[0050] The structure of Salinosporamide A was elucidated by a variety of NMR techniques, mass spectroscopy, IR, and UV spectroscopy, as set forth in Figures 6-14.

[0051] The absolute structure of salinosporamide A, and confirmation of the overall structure of salinosporamide A, was achieved by single-crystal X-ray diffraction analysis (see Example 3).

[0052] The present disclosure describes articles of manufacture including packaging material and a pharmaceutical composition of the invention contained within the packaging material, wherein the packaging material comprises a label which indicates that the pharmaceutical composition can be used for treatment of mammalian cell proliferative disorders. The pharmaceutical composition of the invention may include the compound of the invention in a concentration effective to treat mammalian cell proliferative disorders. The concentration can be determined by one of skill in the art according to standard treatment regimen or as determined by an in vivo animal assay, for example.

[0053] The pharmaceutical compositions of the invention can be used in the form of a solid, a solution, an emulsion, a dispersion, a micelle, a liposome, and the like, wherein the resulting composition contains the compound of the invention as an active ingredient, in admixture with an organic or inorganic carrier or excipient suitable for enteral or parenteral applications. The compound employed for use as a component of the pharmaceutical composition may be combined, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions, and any other form suitable for use. The carriers which can be used include glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, colloidal silica, potato starch, urea, medium chain length triglycerides, dextrans, and other carriers suitable for use in manufacturing preparations, in solid, semisolid, or liquid form. In addition auxiliary, stabilizing, thickening and coloring agents and perfumes may be used.

[0054] The compositions of the present invention may contain other therapeutic agents as described below, and may be formulated, for example, by employing conventional solid or liquid vehicles or diluents, as well as pharmaceutical additives of a type appropriate to the mode of desired administration (for example, excipients, binders, preservatives, stabilizers, flavors, etc.) according to techniques such as those well known in the art of pharmaceutical formulation.

[0055] Invention pharmaceutical compositions may be administered by any suitable means, for example, orally, such as in the form of tablets, capsules, granules or powders; sublingually; buccally; parenterally, such as by subcutaneous, intravenous, intramuscular, or intracisternal injection or infusion techniques (e.g., as sterile injectable aqueous or nonaqueous solutions or suspensions); nasally such as by inhalation spray; topically, such as in the form of a cream or ointment; or rectally such as in the form of suppositories; in dosage unit formulations containing non-toxic, pharmaceutically acceptable vehicles or diluents. The pharmaceutical compositions may, for example, be administered in a form suitable for immediate release or extended release. Immediate release or extended release may be achieved by the use of suitable pharmaceutical compositions comprising the compound of the invention, or, particularly in the case of extended release, by the use of devices such as subcutaneous implants or osmotic pumps.

[0056] The pharmaceutical compositions may be used to inhibit the proliferation of mammalian cells. One embodiment is a use of the pharmaceutical compositions of the invention in a method to inhibit the proliferation of hyperproliferative mammalian cells. For purposes of this invention, "hyperproliferative mammalian cells" are mammalian cells which are not subject to the characteristic limitations of growth, e.g., programmed cell death (apoptosis). A further preferred embodiment is when the mammalian cell is human.

[0057] The present invention provides a pharmaceutical composition as defined herein for use in a method for treating a mammalian cell proliferative disorder. Cell proliferative disorders that can be effectively treated include disorders characterized by the formation of neoplasms. As such, the compound used in the invention is an anti-neoplastic agent. As used herein, "neoplastic" pertains to a neoplasm, which is an abnormal growth, such growth occurring because of a proliferation of cells not subject to the usual limitations of growth. As used herein, "anti-neoplastic agent" is any compound, composition, admixture, comixture or blend which inhibits, eliminates, retards or reverses the neoplastic phenotype of a cell. For the purposes of the invention, the neoplasms are selected from pancreatic adenocarcinoma, central nervous system (CNS), ovarian, prostate, sarcoma of soft tissue or bone, head and neck, gastric which includes thyroid and non-Hodgkin's disease, stomach, myeloma, bladder, neuroendocrine which includes thyroid and non-Hodgkin's disease and Hodgkin's disease neoplasms.

[0058] Chemotherapy, surgery, radiation therapy, therapy with biologic response modifiers, and immunotherapy are currently used in the treatment of cancer. Each mode of therapy has specific indications which are known to those of ordinary skill in the art, and one or all may be employed in an attempt to achieve total destruction of neoplastic cells. Chemotherapy utilizing one or more invention salinosporamide compounds is provided by the present invention. Moreover, combination chemotherapy, chemotherapy utilizing the compound of the invention in combination with other neoplastic agents, is also considered as combination therapy is generally more effective than the use of single anti-neoplastic agents. Thus, the pharmaceutical compositions of the invention may additionally contain at least one other anti-neoplastic agent. Such compositions can also be provided together with physiologically tolerable liquid, gel or solid carriers, diluents, adjuvants and excipients. Such carriers, diluents, adjuvants and excipients may be found in the United States Pharmacopeia Vol. XXII and National Formulary Vol XVII, U.S. Pharmacopeia Convention, Inc., Rockville, Md. (1989). Additional modes of treatment are provided in AHFS Drug Information, 1993 ed. by the American Hospital Formulary Service, pp. 522-660.

[0059] Anti-neoplastic agents which may be additionally used in the inventive compositions include those provided in The Merck Index, 11th ed. Merck & Co., Inc. (1989) pp. Ther 16-17. Anti-neoplastic agents may be antimetabolites which may include, but are not limited to, methotrexate, 5-fluorouracil, 6-mercaptopurine, cytosine arabinoside, hydroxyurea, and 2-chlorodeoxyadenosine. The anti-neoplastic agents contemplated may be alkylating agents which may include, but are not limited to, cyclophosphamide, melphalan, busulfan, paraplatin, chlorambucil, and nitrogen mustard. The antineoplastic agents may be plant alkaloids which may include, but are not limited to, vincristine, vinblastine, taxol, and etoposide. The anti-neoplastic agents contemplated may be antibiotics which may include, but are not limited to, doxorubicin (adriamycin), daunorubicin, mitomycin c, and bleomycin. The anti-neoplastic agents contemplated may be hormones which may include, but are not limited to, calusterone, diomostavolone, propionate, epitiostanol, mepitiostane, testolactone, tamoxifen, polyestradiol phosphate, megesterol acetate, flutamide, nilutamide, and trilotane. The anti-neoplastic agents contemplated may include enzymes which may include, but are not limited to, L-Asparaginase or aminoacridine derivatives which may include, but are not limited to, amsacrine. Additional antineoplastic agents include those provided in Skeel, Roland T, "Antineoplastic Drugs and Biologic Response Modifier: Classification, Use and Toxicity of Clinically Useful Agents," Handbook of Cancer Chemotherapy (3rd ed.), Little Brown & Co. (1991).

[0060] In addition to primates, such as humans, a variety of other mammals can be treated by the compositions of the present invention. For instance, mammals including, but not limited to, cows, sheep, goats, horses, dogs, cats, guinea pigs, rats or other bovine, ovine, equine, canine, feline, rodent or murine species can be treated.

[0061] The term "therapeutically effective amount" means the amount of the subject compound that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician, e.g., lessening of the effects/symptoms of cell proliferative disorders.

[0062] By "pharmaceutically acceptable" it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

[0063] The terms "administration of" and or "administering a" compound should be understood to mean providing a compound of the invention to the individual in need of treatment. Administration of the inventive compositions can be prior to, simultaneously with, or after administration of another therapeutic agent or other anti-neoplastic agent.

[0064] The pharmaceutical compositions for the administration of the compounds of this invention may conveniently be presented in dosage unit form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more accessory ingredients. In general, the pharmaceutical compositions are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation. In the pharmaceutical composition the active object compound is included in an amount sufficient to produce the desired effect upon the process or condition of diseases.

[0065] The pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.

[0066] Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated to form osmotic therapeutic tablets for control release.

[0067] Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.

[0068] Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as saccharin.

[0069] Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

[0070] Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.

[0071] Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol or sorbitol. It will be appreciated that the sucrose required by the inventive pharmaceutical composition may also function as a sweetening agent. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.

[0072] The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

[0073] The compositions of the invention can be administered to mammals for veterinary use, such as for domestic animals, and clinical use in humans in a manner similar to other therapeutic agents. In general, the dosage required for therapeutic efficacy will vary according to the type of use and mode of administration, as well as the particularized requirements of individual hosts. Ordinarily, dosages will range from about 0.001 to 1000 pg/kg, more usually 0.01 to 10 pg/kg, of the host body weight. Alternatively, dosages within these ranges can be administered by constant infusion over an extended period of time, usually exceeding 24 hours, until the desired therapeutic benefits have been obtained. It will be understood, however, that the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.

[0074] The invention will now be described in greater detail by reference to the following non-limiting examples.

EXAMPLES

Methods and Materials [0075] HPLC-Purification of invention compounds was accomplished by RP-MPLC on C18-solid phase (Aldrich) using a step gradient on Kontes Flex-columns (15x7 mm). Semipreparative HPLC was performed on an isocratic HPLC system with a Waters pump 6000H on normal phase column Si-Dynamas-60A (250 x 5 mm) or reversed phase column C18-Dynamax-60A, flow 2 mL/minute, with a differential refractomeric detector Waters R401.

[0076] LC-MS-The LC-MS chromatography was performed on a Hewlett-Packard system series HP1100 with DAD and MSD1100 detection. The separation was accomplished on reversed phase C18 (Agilent Hypersil ODS 5 pm, column dimension 4.6 x 100 mm), flowrate 0.7 mL/minute using a standard gradient: 10% acetonitrile, 15 minutes; 98% acetonitrile (Burdick & Jackson high purity solvents). The MS-detection was in ESI positive mode, capillary voltage 3500 eV, fragmentation voltage 70 eV, mass range mlz 100-1000. The APCI-mode was measured at a flow rate of 0.5 mL/minute, positive detection, capillary voltage 3000 eV, fragmentation voltage 70 eV.

[0077] NMR-NMR spectra were measured on a Varian 300 MHz gradient field spectrometer with inverse-mode for ^ H or 2D-NMR spectra. The 13C and DEPT spectra were measured on a Varian 400 MHz, broad band instrument. Thereference is set on the internal standard tetramethylsilane (TMS, 0.00 ppm).

[0078] MS-El-Low resolution MS-EI spectra were performed on a Hewlett-Packard mass spectrometer with magnetic sector field device, heating rate 20°C/minute up to 320°C, direct injection inlet.

[0079] FTMS-MALDI- High resolution MS data were obtained by MALDI operating mode on an lonSpec Ultima FT Mass Spectrometer.

[0080] IR-Infrared spectra were measured on a Perkin-Elmer FT infrared spectrophotometer using NaCI windows.

Reference Example 1

Isolation and Characterization of "Salinsospora" species, Culture Nos. CNB392 and CNB476 [0081] CNB392 and CNB476 possess signature nucleotides within their 16S rDNA which separate these strains phylogenetically from all other members of the family Micromonosporaceae (see Figure 15) These signature nucleotides have been determined to be a definitive marker for members of this group which also have a physiological growth requirement of sodium. Signature nucleotides were aligned to E. coll positions 27-1492 using all existing members of the Micromonosporaceae in the Ribosomal Database Project as of 1-31-01. For the "Salinospora" clade, 45 partially sequenced morphotypes displayed all the signature nucleotides from positions 207-468. The seven "Salinospora" isolates sequenced almost in their entirety (see Figure 2) displayed all of the signatures in Figure 15.

[0082] The strains CNB392 and CNB476 form bright orange to black colonies on agar and lacks aerial mycelia. Dark brown and bright orange diffusible pigments are produced depending upon cellular growth stage. Spores blacken the colony surface and are borne on substrate mycelia. Vegetative mycelia are finely branched and do not fragment. Spores are produced singly or in clusters. Neither sporangia nor spore motility has been observed for these strains. CNB392 and CNB476 have an obligate growth requirement for sodium and will not grow on typical media used for maintenance of other generic members of the Micromonosporaceae. CNB392 and CNB476 have been found to grow optimally on solid media TCG or M1 at 30°C.

Fermentaion [0083] CNB392 and CNB476 are cultured in shaken AIBfe+C or CKA-liquid media, 1 liter at 35°C for 9 days. After 4 days 20 grams Amberlite XAD-16 resin (Sigma, nonionic polymeric adsorbent) is added.

Extraction [0084] The XAD-16 resin is filtered and the organic extract is eluted with 1 liter ethylacetate followed by 1 liter methanol. The filtrate is then extracted with ethylacetate (3 x200 mL). The crude extract from the XAD adsorption is 105 mg. Cytotoxicity on the human colon cancer cell HCT-116 assay is IC50 < 0.076 pg/mL.

Isolation of Salinosporamide A from CNB392 [0085] The crude extract was flash-chromatographed over C 18 reversed phase (RP) using a step gradient (Figure 5). The HCT-116 assay resulted in two active fractions, CNB392-5 and CNB392-6. The combined active fractions (51.7 mg), HCT-116 < 0.076 pg/mL) were then chromatographed on an isocratic RP-HPLC, using 85% methanol at 2 mL/minute flow as eluent and using refractive index detection. The active fraction CNB392-5/6 (7.6 mg, HCT-116 < 0.076 pg/mL) was purified on an isocratic normal phase HPLC on silica gel with ethyl acetate:isooctane (9: 1) at 2 mL/minute. Salinosporamide A (Figure 1) was isolated as a colorless, amorphous solid in 6.7 mg per 1 liter yield (6.4 %). TLC on silica gel (dichloromethane:methanol 9:1) shows Salinosporamide A at rf = 0.6, no UV extinction or fluorescence at 256 nm,yellow with H2SC>4/ethanol, dark red-brown with Godin reagent (vanillin/H2S04/HCI04). Salinosporamide A is soluble in CHCI3, methanol, and other polar solvents like DMSO, acetone, acetonitrile, benzene, pyridine, Ν,Ν-dimethyformamide, and the like. 1H NMR: (ds-pyridine, 300 MHz) 1.37/1.66 (2H, m, CH2), 1,.70.2.29 (2H, m, CH2), 1.91 (2H, broad, CH2), 2.07 (3H, s, CH3), 2.32/2.48 (2H, ddd, 3J = 7.0 Hz, CH2), 2.85 (1H, broad, m, CH), 3.17 (1H, dd, 3J= 10 Hz, CH), 4.01/4.13 (2H, m, CH2), 4.25 (1H, d, 3J = 9.0 Hz, CH), 4.98 (1H, broad, OH), 5.88, (1H, ddd, 3J = 10 Hz, CH), 6.41 (1H, broad d, 3J= 10 Hz, CH) 10.62 (1H, s, NH). 13C NMR/DEPT: (d 5-pyridine, 400 MHz) 176.4 (COOR), 169.0 (CONH), 128.8 (=CH), 128.4 (=CH), 86.1 (Cq), 80.2 (Cq), 70.9 (CH), 46.2 (CH), 43.2 (CH2), 39.2 (CH), 29.0 (Cl^), 26.5 (CH2), 25.3 (CH2), 21.7 (CH2), 20.0 (CH3) LC-MS (ESI) tr= 10.0 minutes, flow 0.7 mL/minute m/z: (M+H)+ 314, (M+Na)+ 336; fragments: (M+H-C02)+ 292, (M+H-C02-H20)+ 270, 252, 204. Cl pattern: (M+H, 100%)+ 314, (M+H, 30 %)+ 316. LC MS (APCI): tr = 11.7 minutes, flow 0.5 mL/minute m/z: (M+H)+314, fragments: (M+H-C02-H20)+270, 252, 232, 216, 160. Cl pattern: (M+H, 100%)+ 314, (M+H, 30 %)+316.

El: m/z: 269, 251,235, 217, 204, 188 (100%), 160, 152, 138, 126, 110,81. FTMS-MALDI: m/z: (M+H)+314.1144 FT-IR: (cm’1) 2920, 2344, s, 1819 m, 1702 s, 1255, 1085 s, 1020 s, 797 s.

Molecular formula: C-|5H2oCIN04

Reference Example 2 Bioactivity Assays [0086] Salinosporamide A shows strong activity against human colon cancer cells with an 1C 50 of 0.011 pg/mL (see Figure 4). The screening on antibacterial or antifungal activity shows no significant activity, see Table 1.

Table 1

Reference Example 3

Determination of Absolute Stereochemistry [0087] Crystallization of a compound of structure I from ethyl acetate//so-octane resulted in single, cubic crystals, which diffracted as a monoclinic system P2(1). The unusual high unit-cell volume of 3009 A hosted four independent molecules in which different conformational positions were observed for the flexible chloroethyl substituent. The assignment of the absolute structure from the diffraction anisotropy of the chlorine substituent resolved the absolute stereochemistry of salinosporamide A as 2R,3S,4R,5S,6S (Figures 16 and 17) with a Flack parameter of 0.01 and an esd of 0.03.

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description • W02005002572A ΓΟΟΟβΙ F00061 • WQ20Q4071382A [00071 [00081

Non-patent literature cited in the description . ROBERT H. FELING et al.Angew. Chem. Int. Ed., 2003, vol. 42, 3355-357 [6004] • WILLIAM FENICAL et al.Pharmaceutical News, 2002, vol. 9, 480-494 [0005] • United States Pharmacopeia, vol. XXII, 10.041] {0058} • National FormularyU.S. Pharmacopeia Convention, Inc. 19890000vol. XVII, [0041] [0058] • AFIFS Drug InformationAmerican Hospital Formulary Servicel9930000522-660 [0058] • Antineoplastic Drugs and Biologic Response Modifier: Classification, Use and Toxicity of Clinically Useful Agents SKEEL, ROLAND T.Handbook of Cancer ChemotherapyLittle Brown & Co. 19910000 [0059]

Claims

1. Farmaceutisk sammensætning omfattende en effektiv mængde af en farmaceutisk acceptabel bærer og en effektiv mængde af en forbindelse med strukturen af forbindelsen (V):A pharmaceutical composition comprising an effective amount of a pharmaceutically acceptable carrier and an effective amount of a compound having the structure of the compound (V):

hvori den farmaceutiske sammensætning yderligere omfatter sukrose.wherein the pharmaceutical composition further comprises sucrose.

2. Farmaceutisk sammensætning ifølge krav 1, hvori den farmaceutiske sammensætning er i form af en injicérbar steril opløsning eller et fast stof.The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is in the form of an injectable sterile solution or solid.

3. Farmaceutisk sammensætning ifølge krav 2, hvori den injicérbare sterile opløsning er en vandig injicérbar steril opløsning.The pharmaceutical composition of claim 2, wherein the injectable sterile solution is an aqueous injectable sterile solution.

4. Farmaceutisk sammensætning ifølge ethvert af krav 1 til 3, hvori den farmaceutiske sammensætning yderligere omfatter et yderligere middel.The pharmaceutical composition of any one of claims 1 to 3, wherein the pharmaceutical composition further comprises an additional agent.

5. Farmaceutisk sammensætning ifølge ethvert af krav 1 til 4 til anvendelse ved behandling af en proliferativ pattedyrscellelidelse, hvori lidelsen er valgt fra gruppen bestående af bugspytkirteladenokarcinom, centralnervesystemneoplasma, sarkom af blødt væv, sarkom af knogle, hovedneoplasma, halsneoplasma, gastrisk neoplasma, skjoldbruskkirtelneoplasma, maveneoplasma, myelom, blære-neoplasma, neuroendokrin neoplasma, non-Flodgkins sygdom neoplasma og Flod-gkins sygdom neoplasma.A pharmaceutical composition according to any one of claims 1 to 4 for use in the treatment of a proliferative mammalian cell disorder wherein the disorder is selected from the group consisting of pancreatic adenocarcinoma, central nervous system neoplasm, soft tissue sarcoma, bone neoplasm, gastric neoplasm, gastric neoplasm, gastric neoplasm stomach neoplasm, myeloma, bladder neoplasm, neuroendocrine neoplasm, non-Flodgkin's disease neoplasm and Flodgkin's disease neoplasm.

6. Farmaceutisk sammensætning til anvendelse ifølge krav 5, hvori pattedyrscellen er human.The pharmaceutical composition for use according to claim 5, wherein the mammalian cell is human.